FDA Approves Susvimo For Diabetic Macular Edema Treatment

FDA approves ranibizumab for treating diabetic macular edema
The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the treatment of diabetic macular edema (DMO). According to the company,
FDA approves continuous delivery ranibizumab injection (Susvimo) for the treatment of diabetic macular edema
Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure, continuously delivering a customized formulation of ranibizumab over time.
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susv
Roche gains label expansion for eye implant Susvimo to treat diabetic macular edema
Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened its label as a treatment for diabetic macular edema (DME), which is the leading cause of diabetes-related blindness.
FDA Approves Susvimo for Diabetic Macular Edema
Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a refillable ocular implant.
Genentech : FDA Approves Susvimo For Diabetic Macular Edema Treatment
Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo
With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech initially won Food and Drug Administration approval of the refillable implant in 2021 for patients with we
Macular Degeneration Treatment Market Size is Projected to Reach USD 18.59 Billion by 2033, Growing at a CAGR of 7.06%: Straits Research
The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...
These smart glasses help people with macular degeneration by eliminating blind spots
Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.
Flow Space on MSN7d
Judi Dench Lost Her Vision to Macular Degeneration-What Every Woman Should Know
Macular degeneration is a leading cause of vision loss for people over 50, but there are ways to help protect your eyesight.
Astellas seeks conditional approval for GA treatment in Japan
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
Macular Degeneration Treatment Market Size, Top Share, Forecast To 2033
Introduction The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of centr ...
EyePoint stock jumps 10% on Duravyu study results
EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.
Serious eye disease Age-Related Macular Degeneration (AMD) recognized with official awareness month: Canadian Ophthalmological Society
The unique challenges, and need for awareness, of age-related macular degeneration (AMD) is now formally recognized in Canada ...